Comparison between immune response to different modes of vaccination: intradermal and subcutaneous yellow fever vaccination

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN46326316

Enrollment

120

Registered

2005-12-20

Start date

2005-06-15

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Yellow Fever Infections and Infestations Yellow Fever

Interventions

Subcutaneous of intradermal yellow fever vaccination.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy volunteers, greater than 18 years (previously and not previously vaccinated with yellow fever vaccine)

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Diabetes mellitus 3. Use of immunomodulating medication, e.g. corticosteroids 4. Cytostatica 5. Use of chloroquine

Design outcomes

Primary

Measure	Time frame
1. Protective humoral immune response 2. For first time vaccinees measured 4 and 8 weeks post-vaccination, for revaccinees measured 2 weeks post-vaccination. 3. All sera will be analysed by ELISA, Immunofluorescence and plaque reduction assay.	—

Secondary

Measure	Time frame
Adverse events measured for three weeks post-vaccination by keeping a diary, viremia measured 5 days post-vaccination by RT-PCR.	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 5, 2026